Stockreport

Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3 [Seeking Alpha]

Ocugen, Inc.  (OCGN) 
PDF 14min Summary Ocugen continues advancing its gene therapy pipeline, with OCU400 in Phase 3 trials for retinitis pigmentosa, targeting FDA approval by 2026. OCU400 [Read more]